Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer

Autor: Giulia Schiavoni, Beatrice Messina, Stefano Scalera, Lorenzo Memeo, Cristina Colarossi, Marzia Mare, Giovanni Blandino, Gennaro Ciliberto, Giulia Bon, Marcello Maugeri-Saccà

Publikováno v: Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-16 (2024)

Abstract Background First identified in Drosophila melanogaster, the Hippo pathway is considered a major regulatory cascade controlling tissue homeostasis and organ development. Hippo signaling components include kinases whose activity regulates YAP

Externí odkaz: https://doaj.org/article/c14aefa5d7e340788e63b87dea7ef150

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

Autor: Giulia Bon, Eriseld Krasniqi, Manuela Porru, Lorenzo D'Ambrosio, Stefano Scalera, Marcello Maugeri-Saccà, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Andrea Botticelli, Daniele Santini, Maria Agnese Fabbri, Giuliana D'Auria, Claudio Pulito, Giovanni Blandino, Caterina Marchiò, Maddalena Barba, Gennaro Ciliberto, Patrizia Vici, Laura Pizzuti

Publikováno v: Neoplasia: An International Journal for Oncology Research, Vol 45, Iss , Pp 100937- (2023)

The therapeutic scenario of Human Epidermal Growth Factor Receptor 2 positive advanced breast cancer (ABC) has been recently enriched by a number of innovative agents, which are reshaping treatment sequence. While randomized trials have documented an

Externí odkaz: https://doaj.org/article/f29fae04ef374dc0bbefa7906732c0e1

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Autor: Rossella Loria, Valentina Laquintana, Stefano Scalera, Rocco Fraioli, Valentina Caprara, Italia Falcone, Chiara Bazzichetto, Marta Di Martile, Laura Rosanò, Donatella Del Bufalo, Gianluca Bossi, Isabella Sperduti, Irene Terrenato, Paolo Visca, Silvia Soddu, Michele Milella, Gennaro Ciliberto, Rita Falcioni, Virginia Ferraresi, Giulia Bon

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-18 (2022)

Abstract Background Despite the promise of dual BRAF/MEK inhibition as a therapy for BRAF-mutant (BRAF-mut) melanoma, heterogeneous responses have been observed in patients, thus predictors of benefit from therapy are needed. We have previously ident

Externí odkaz: https://doaj.org/article/ab827d306d054785a82dd587f4b896b6

Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

Autor: Rossella Loria, Patrizia Vici, Francesca Sofia Di Lisa, Silvia Soddu, Marcello Maugeri-Saccà, Giulia Bon

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

Over the past two decades, cancer treatment has benefited from having a significant increase in the number of targeted drugs approved by the United States Food and Drug Administration. With the introduction of targeted therapy, a great shift towards

Externí odkaz: https://doaj.org/article/215b19b544924dc3b3f9b7f27c90571e

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Autor: Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D’Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D’Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Saccà, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnarò, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto, Patrizia Vici

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)

Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is still debated. To address this

Externí odkaz: https://doaj.org/article/8be0edebe30b47389bcf83b804b70b94